Medical 21, Inc. — SEC Form D Filing

Medical 21, Inc. filed an SEC Form D on October 22, 2026, reporting $550K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 22, 2026
Amount reported
$550K
Round stage
Seed stage based on the small $550,000 equity financing round intended for preliminary development and regulatory filing preparations.
Industry
Biotechnology
Website
https://medical21.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: MINNESOTA

Problem

Coronary artery bypass surgeries currently require harvesting a patient's own blood vessels, creating additional surgical incisions, pain, complications, and extended recovery times.

Solution

Medical 21 builds the Maverics regenerative artificial artery, a synthetic graft featuring a resorbable polymer scaffold and nitinol reinforcement that eliminates the need to harvest host vessels.

Why now

Recent advancements in bioresorbable polymers and micro-structural nitinol fabrication now allow artificial grafts to support tissue regeneration and safely reabsorb into the body.

Source: SEC EDGAR Form D filing